Author: Benzinga Newsdesk | August 12, 2025 06:33am
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.54) by 7.41 percent. This is a 97.37 percent increase over losses of $(19.01) per share from the same period last year.